President and Chief Medical Officer · Prelude Therapeutics Inc (PRLD)

Jane Huang

A named executive officer of Prelude Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,654,662

Salary $545,833Stock awards $0

FY2022: $2,920,215

2nd of 3 named executive officers at Prelude Therapeutics by FY2023 total.

3 named officers on file for Prelude Therapeutics, FY2023

Jane Huang’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Prelude Therapeutics’s whole pay program stands against its peers

  • Prelude Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PRLD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jane Huang’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jane Huang compensation by year

Prelude Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Prelude Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$391,761$545,833
Bonus$4,450$0
Stock awards$729,000$0
Option awards$1,627,660$789,033
Non-equity incentive$167,344$316,250
Pension and deferred compensation$0$0
All other$0$3,546
Total$2,920,215$1,654,662

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Prelude Therapeutics Inc DEF 14A filed April 26, 2024, accession 0000950170-24-049126, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Prelude Therapeutics Inc filed document, accession 0000950170-24-049126. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$2.9M
$1.7M
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU93,750$400,313—
Option150,000—$7.20
Option268,334—$4.86

Per the Outstanding Equity Awards at Fiscal Year-End table in Prelude Therapeutics Inc's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

19 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-10-04Tax withholding—3,355$1.4786,917
2025-10-04Exercise or conversion—9,375—90,272
2025-10-04Exercise or conversion derivative—9,375$0.0018,750
2025-07-04Tax withholding—3,355$0.7980,897
2025-07-04Exercise or conversion derivative—9,375$0.0028,125
2025-07-04Exercise or conversion—9,375—84,252
2025-04-04Exercise or conversion derivative—9,375$0.0037,500
2025-04-04Exercise or conversion—9,375—78,232

The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Prelude Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Krishna VaddiChief Executive Officer$2,641,789
Jane Huang · this pagePresident and Chief Medical Officer$1,654,662
Bryant LimChief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer$1,614,766

The full Prelude Therapeutics compensation record

free company brief

This page is one person within Prelude Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Prelude Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jane Huang's compensation dossier · One-time report. No refunds.